<DOC>
	<DOCNO>NCT00436163</DOCNO>
	<brief_summary>This single-arm study evaluate efficacy safety peginterferon alfa-2a treatment-naive Baltic participant Hepatitis B envelope antigen ( HBeAg ) -positive chronic Hepatitis B virus ( HBV ) . All participant receive peginterferon alfa-2a 180 microgram ( mcg ) subcutaneously weekly . Following 48 week treatment , 24 week period treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size le 100 participant .</brief_summary>
	<brief_title>A Study Peginterferon Alfa-2a ( 40KD ) ( PEGASYSÂ® ) Participants With Hepatitis B Envelope Antigen ( HBeAg ) - Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participant , 1870 year age ; HBeAg positive , Hepatitis B surface antigen ( HBsAg ) positive great equal 6 month ; antiHBs negative ; Hepatitis B virus deoxyribonucleic acid ( HBV DNA ) great 5,00,000 copies/milliliters . Previous antiviral interferonbased therapy chronic hepatitis B ; Evidence decompensated liver disease ; Chronic liver disease viral hepatitis ; Coinfection active hepatitis A , C D virus ; Coinfection human immunodeficiency virus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>